HYL — Hyloris Pharmaceuticals SA Share Price
Last trade - 00:00- €175.28m
- €153.32m
- €8.46m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 8.14% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.45 | ||
| Price to Tang. Book | 6.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 20.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.86% | ||
| Return on Equity | -17.81% | ||
| Operating Margin | -84.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.17 | 3.1 | 0.9 | 2.09 | 8.46 | 13.1 | 50.83 | 147.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hyloris Pharmaceuticals SA is a Belgium-based bio-pharmaceutical company. The Company focus is on re-engineering cardiovascular products with a wide range of therapeutic indications and dosage forms. It has two partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain. Additionally, it develops the strategy of reformulating and repurposing already-approved pharmaceuticals primarily utilize the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for the safety and efficacy. It also creates new and different solutions for the approved pharmaceuticals along with the technological requirements.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 31st, 2017
- Public Since
- June 29th, 2020
- No. of Employees
- 40
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Brussels
- Shares in Issue
- 28,000,374
- Address
- Boulevard Patience et Beaujonc, LIEGE, 4000
- Web
- https://hyloris.com/
- Phone
- +32 43460207
- Auditors
- KPMG Bedrijfsrevisoren
Upcoming Events for HYL
Similar to HYL
Biosenic SA
Euronext - Brussels
Fagron NV
Euronext - Brussels
Financiere de Tubize SA
Euronext - Brussels
UCB SA
Euronext - Brussels
FAQ
As of Today at 12:12 UTC, shares in Hyloris Pharmaceuticals SA are trading at €6.26. This share price information is delayed by 15 minutes.
Shares in Hyloris Pharmaceuticals SA last closed at €6.26 and the price had moved by -46.5% over the past 365 days. In terms of relative price strength the Hyloris Pharmaceuticals SA share price has underperformed the FTSE Global All Cap Index by -48.73% over the past year.
The overall consensus recommendation for Hyloris Pharmaceuticals SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHyloris Pharmaceuticals SA does not currently pay a dividend.
Hyloris Pharmaceuticals SA does not currently pay a dividend.
Hyloris Pharmaceuticals SA does not currently pay a dividend.
To buy shares in Hyloris Pharmaceuticals SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €6.26, shares in Hyloris Pharmaceuticals SA had a market capitalisation of €175.28m.
Here are the trading details for Hyloris Pharmaceuticals SA:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: HYL
Based on an overall assessment of its quality, value and momentum Hyloris Pharmaceuticals SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hyloris Pharmaceuticals SA is €14.00. That is 123.64% above the last closing price of €6.26.
Analysts covering Hyloris Pharmaceuticals SA currently have a consensus Earnings Per Share (EPS) forecast of -€0.34 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hyloris Pharmaceuticals SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -3.79%.
As of the last closing price of €6.26, shares in Hyloris Pharmaceuticals SA were trading +8.73% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hyloris Pharmaceuticals SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €6.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Hyloris Pharmaceuticals SA's directors